title: Anti-CD25 antibody (daclizumab) maintenance therapy in pancreas transplantation.
abstract: BACKGROUND
  Calcineurin inhibitors (CNI) are the basis of contemporary immunosuppression in clinical pancreas transplantation (PT). Nevertheless, CNI toxicities, especially nephrotoxicity, have stimulated the search for CNI-sparing protocols. We performed a retrospective analysis of 25 PT patients with progressive CNI toxicities that were switched to a daclizumab (DAC)-based maintenance regimen.
  
  
  METHODS
  From 2003 to 2007, 25 PT patients with progressive CNI toxicity (predominantly nephrotoxicity) were identified and switched from CNI to monthly DAC maintenance therapy. The DAC group was compared with matched control subjects (1:1) by transplant type and number, age, year of transplant, and duct management.
  
  
  CONCLUSIONS
  Results showed improved graft survival rates and decreased immunologic loss rates at 1, 3, and 5 years in the DAC group compared with the control group. There was no difference in patient survival rate between the 2 groups. Analysis demonstrates that DAC maintenance therapy is safe and effective for PT patients experiencing CNI toxicities. A randomized trial to compare DAC- and CNI-based regimens is needed in CNI-intolerant patients, with particular attention to the impact on renal function and patient morbidity (eg, infection rates).
authors.affiliation: Schulze Diabetes Institute, University of Minnesota, Minneapolis, Minnesota, USA.
authors.forename: V A
authors.initials: VA
authors.lastname: Kirchner
authors.forename: T M
authors.initials: TM
authors.lastname: Suszynski
authors.forename: D M
authors.initials: DM
authors.lastname: Radosevich
authors.forename: A
authors.initials: A
authors.lastname: Humar
authors.forename: T B
authors.initials: TB
authors.lastname: Dunn
authors.forename: M J
authors.initials: MJ
authors.lastname: Hill
authors.forename: E B
authors.initials: EB
authors.lastname: Finger
authors.forename: D E R
authors.initials: DE
authors.lastname: Sutherland
authors.forename: R
authors.initials: R
authors.lastname: Kandaswamy
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D005500:Follow-Up Studies; D006085:Graft Survival / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D053645:Interleukin-2 Receptor alpha Subunit / Q000276:immunology; D016030:Kidney Transplantation / Q000276:immunology / Q000706:statistics & numerical data; D008875:Middle Aged; D016035:Pancreas Transplantation / Q000276:immunology* / Q000401:mortality; D012086:Reoperation / Q000706:statistics & numerical data; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D053645:Interleukin-2 Receptor alpha Subunit; D000077561:Daclizumab